<DOC>
	<DOC>NCT01033357</DOC>
	<brief_summary>The purpose of this study is to determine whether the long term use of the experimental Vascular Wrap(TM) Paclitaxel-Eluting Mesh is safe in the treatment of subjects needing hemodialysis access (via an expanded polytetrafluoroethylene (ePTFE) graft).</brief_summary>
	<brief_title>Safety Study of the Vascular Wrap Paclitaxel-Eluting Mesh for Hemodialysis Vascular Access</brief_title>
	<detailed_description>The primary objective of this study is to determine long term safety of the Lifespan® ePTFE Vascular Graft and Vascular Wrap(TM) Paclitaxel-Eluting Mesh in comparison to the Lifespan® graft alone.</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>To be considered for enrollment, subjects must: have been randomized in protocol 012VWAV06; have signed and dated an IRBapproved written informed consent to participate in 012VWAV06 as well as this study; be willing to comply with all aspects of the evaluation schedule over a period of 60 months post device insertion; allow representatives of the sponsor, designated Clinical Research Organization (CRO), Institutional Review Board (IRB), the Ethics Committee, and U.S. Food and Drug Administration (FDA) to review his/her relevant medical records. Subjects who withdrew or were withdrawn from study 012VWAV06.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>dialysis</keyword>
	<keyword>hemodialysis</keyword>
	<keyword>neointimal hyperplasia</keyword>
</DOC>